DocuSign, Inc. (NASDAQ:DOCU) Shares Sold by Geneos Wealth Management Inc.

Geneos Wealth Management Inc. lowered its position in DocuSign, Inc. (NASDAQ:DOCU) by 5.0% in the fourth quarter, Holdings Channel.com reports. The firm owned 3,444 shares of the company’s stock after selling 182 shares during the quarter. Geneos Wealth Management Inc.’s holdings in DocuSign were worth $205,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors also recently added to or reduced their stakes in DOCU. Vanguard Group Inc. lifted its holdings in shares of DocuSign by 2.4% in the 3rd quarter. Vanguard Group Inc. now owns 20,982,387 shares of the company’s stock valued at $881,260,000 after buying an additional 482,472 shares during the period. Capital World Investors lifted its holdings in DocuSign by 128.3% in the first quarter. Capital World Investors now owns 5,683,838 shares of the company’s stock valued at $608,853,000 after acquiring an additional 3,193,727 shares during the period. Morgan Stanley lifted its holdings in DocuSign by 1.7% in the third quarter. Morgan Stanley now owns 3,219,450 shares of the company’s stock valued at $135,217,000 after acquiring an additional 53,553 shares during the period. Clearbridge Investments LLC boosted its position in shares of DocuSign by 1.9% during the 1st quarter. Clearbridge Investments LLC now owns 3,186,783 shares of the company’s stock worth $341,368,000 after purchasing an additional 58,555 shares in the last quarter. Finally, Renaissance Technologies LLC grew its stake in shares of DocuSign by 0.3% during the 1st quarter. Renaissance Technologies LLC now owns 2,872,900 shares of the company’s stock worth $167,490,000 after purchasing an additional 8,300 shares during the period. Hedge funds and other institutional investors own 77.64% of the company’s stock.

Insiders Place Their Bets

In other news, Director Peter Solvik sold 15,000 shares of the firm’s stock in a transaction on Tuesday, April 9th. The stock was sold at an average price of $60.00, for a total transaction of $900,000.00. Following the sale, the director now owns 783 shares in the company, valued at $46,980. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other DocuSign news, Director Teresa Briggs sold 499 shares of the stock in a transaction that occurred on Thursday, February 29th. The shares were sold at an average price of $52.99, for a total transaction of $26,442.01. Following the transaction, the director now owns 6,169 shares of the company’s stock, valued at $326,895.31. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director Peter Solvik sold 15,000 shares of the business’s stock in a transaction on Tuesday, April 9th. The shares were sold at an average price of $60.00, for a total transaction of $900,000.00. Following the sale, the director now directly owns 783 shares of the company’s stock, valued at $46,980. The disclosure for this sale can be found here. In the last three months, insiders sold 54,871 shares of company stock valued at $3,176,199. Company insiders own 17.80% of the company’s stock.

Analysts Set New Price Targets

A number of analysts recently commented on DOCU shares. Morgan Stanley raised shares of DocuSign from an “underweight” rating to an “equal weight” rating and boosted their price objective for the stock from $49.00 to $64.00 in a report on Tuesday, January 16th. Needham & Company LLC reissued a “hold” rating on shares of DocuSign in a research note on Friday. JMP Securities reaffirmed a “market outperform” rating and issued a $84.00 price objective on shares of DocuSign in a research note on Friday. Wells Fargo & Company decreased their target price on DocuSign from $55.00 to $45.00 and set an “underweight” rating on the stock in a research report on Monday, February 5th. Finally, TheStreet upgraded DocuSign from a “d+” rating to a “c-” rating in a research report on Tuesday, December 19th. Two equities research analysts have rated the stock with a sell rating, seven have given a hold rating and two have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $60.25.

DocuSign Trading Down 1.0 %

DocuSign stock opened at $58.90 on Monday. The stock has a 50-day moving average price of $55.37 and a 200 day moving average price of $51.73. DocuSign, Inc. has a 52 week low of $38.11 and a 52 week high of $64.76. The stock has a market cap of $12.10 billion, a PE ratio of 163.62, a P/E/G ratio of 5.15 and a beta of 0.89.

DocuSign (NASDAQ:DOCU) last issued its quarterly earnings results on Thursday, March 7th. The company reported $0.15 EPS for the quarter, topping analysts’ consensus estimates of $0.09 by $0.06. The business had revenue of $712.39 million during the quarter, compared to the consensus estimate of $698.05 million. DocuSign had a net margin of 2.68% and a return on equity of 13.91%. On average, equities analysts predict that DocuSign, Inc. will post 0.86 EPS for the current year.

DocuSign Company Profile

DocuSign, Inc provides electronic signature solution in the United States and internationally. The company provides e-signature solution that enables sending and signing of agreements on various devices; Contract Lifecycle Management (CLM), which automates workflows across the entire agreement process; Document Generation streamlines the process of generating new, custom agreements; and Gen for Salesforce, which allows sales representatives to automatically generate agreements with a few clicks from within Salesforce.